Subsequent to the recent publication of the IPASS study, gefitinib was awarded license for the treatment of first line, chemotherapy naive advanced or metastatic patients with NSCLC based upon molecular stratification for the presence of activating somatic EGFR mutations[13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.